The interaction of PD-1 receptor on CD8+ T cells and its ligand PD-L1 on tumor cells mediates tumor progression and helps the tumor to escape immune surveillance as described in malignancies including melanoma, non-small cell lung carcinoma, colorectal cancer, and renal cell carcinoma (35–37). Here, CD8A is linked to melanoma.